慢阻肺或哮喘患者使用吸入性糖皮质激素与COVID-19相关死亡风险:基于OpenSAFELY平台的观察性队列研究
该研究利用英国OpenSAFELY平台链接的电子健康记录,分析慢阻肺和哮喘患者中使用吸入性糖皮质激素(ICS)与COVID-19相关死亡的关系。结论不支持ICS对COVID-19死亡有保护作用,观察到的风险增加可能由疾病严重程度等未测量混杂解释。
要点
- 低中剂量ICS未显示显著风险增加,结果可能受未测量混杂影响。
核心结论
- 结果不支持常规使用ICS对哮喘或慢阻肺患者COVID-19相关死亡有保护作用。
- 观察到的风险增加可能由疾病严重程度等未测量混杂解释。
研究设计与样本
- 观察性队列研究,使用OpenSAFELY平台链接英格兰初级保健电子健康记录与死亡数据。
- 慢阻肺患者需年龄≥35岁、当前或既往吸烟、4个月内处方ICS或LABA-LAMA组合。
- 哮喘患者需年龄≥18岁、3年内诊断哮喘、4个月内处方ICS或仅SABA。
- 采用Cox回归模型估计风险比(HR)和95%CI,并计算E值。
临床怎么用
- 临床不应为预防COVID-19相关死亡而常规处方ICS。
- 对于慢阻肺或哮喘患者,应基于原有适应证评估ICS使用,并考虑疾病严重程度等混杂因素。
局限性
- 观察性设计可能受未测量混杂影响,尤其是疾病严重程度。
- E值分析提示相对较小的未测量混杂即可解释观察到的风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early descriptions of patients admitted to hospital during the COVID-19 pandemic showed a lower prevalence of asthma and chronic obstructive pulmonary disease (COPD) than would be expected for an acute respiratory disease like COVID-19, leading to speculation that inhaled corticosteroids (ICSs) might protect against infection with severe acute respiratory syndrome coronavirus 2 or the development of serious sequelae. We assessed the association between ICS and COVID-19-related death among people with COPD or asthma using linked electronic health records (EHRs) in England, UK. METHODS: In this observational study, we analysed patient-level data for people with COPD or asthma from primary care EHRs linked with death data from the Office of National Statistics using the OpenSAFELY platform. The index date (start of follow-up) for both cohorts was March 1, 2020; follow-up lasted until May 6, 2020. For the COPD cohort, individuals were eligible if they were aged 35 years or older, had COPD, were a current or former smoker, and were prescribed an ICS or long-acting β agonist plus long-acting muscarinic antagonist (LABA-LAMA) as combination therapy within the 4 months before the index date. For the asthma cohort, individuals were eligible if they were aged 18 years or older, had been diagnosed with asthma within 3 years of the index date, and were prescribed an ICS or short-acting β agonist (SABA) only within the 4 months before the index date. We compared the outcome of COVID-19-related death between people prescribed an ICS and those prescribed alternative respiratory medications: ICSs versus LABA-LAMA for the COPD cohort, and low-dose or medium-dose and high-dose ICSs versus SABAs only in the asthma cohort. We used Cox regression models to estimate hazard ratios (HRs) and 95% CIs for the association between exposure categories and the outcome in each population, adjusted for age, sex, and all other prespecified covariates. We calculated e-values to quantify the effect of unmeasured confounding on our results. FINDINGS: We identified 148 557 people with COPD and 818 490 people with asthma who were given relevant respiratory medications in the 4 months before the index date. People with COPD who were prescribed ICSs were at increased risk of COVID-19-related death compared with those prescribed LABA-LAMA combinations (adjusted HR 1·39 [95% CI 1·10-1·76]). Compared with those prescribed SABAs only, people with asthma who were prescribed high-dose ICS were at an increased risk of death (1·55 [1·10-2·18]), whereas those given a low or medium dose were not (1·14 [0·85-1·54]). Sensitivity analyses showed that the apparent harmful association we observed could be explained by relatively small health differences between people prescribed ICS and those not prescribed ICS that were not recorded in the database (e value lower 95% CI 1·43). INTERPRETATION: Our results do not support a major role for regular ICS use in protecting against COVID-19-related death among people with asthma or COPD. Observed increased risks of COVID-19-related death can be plausibly explained by unmeasured confounding due to disease severity. FUNDING: UK Medical Research Council.
引用
- Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020. PMID: 32979987. doi:10.1016/S2213-2600(20)30415-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。